Aggarwal and Girard Analyze Data Amassed With Durvalumab in Unresectable Stage III NSCLC

Season 5 Episode 45  ·  Sep 27, 2021, 07:15 PM

Headliner
Share
Subscribe

Dr. Aggarwal and Dr. Girard discuss the significance of the 5-year survival data from the pivotal PACIFIC trial and the real-world benefit of the study regimen in patients with unresectable stage III NSCLC.

Share
Subscribe
Next
Genomically Guided Radiation Dosing in Oncology: Ready for Prime Time?
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air